1 heavyweight FTSE 100 share I’d buy as London retakes its crown

Some Footsie firms are extremely large, but that doesn’t mean they couldn’t get even bigger. Here’s one such FTSE 100 share I’d buy right now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

British flag, Big Ben, Houses of Parliament and British flag composition

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

After surging to record highs in May, FTSE 100 shares have since come off the boil a bit. But not as much as those in France, where the CAC All-Share index has fallen by around 7.4% in one month.

The index has been driven lower by uncertainty about the outcome of the nation’s looming parliamentary elections. And it means that London retook its title as Europe’s largest stock market from Paris on 17 June.

That said, a quick rebound in giant luxury stocks like Hermes International and LVMH across the Channel could quickly reverse that. It’s neck and neck.

Should you invest £1,000 in HSBC right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if HSBC made the list?

See the 6 stocks

Still, it’s encouraging to see UK blue-chip stocks getting some love recently. Valuations are attractive and dividends are high, which has been attracting overseas investors.

Here is one Footsie stock that I’d buy today, despite its enormous size.

Still growing strongly

I’m talking about AstraZeneca (LSE: AZN), which is London’s largest firm with a market cap of £192bn.

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALL20 Jun 201920 Jun 2024Zoom ▾Jul '19Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '242020202020212021202220222023202320242024www.fool.co.uk

The first thing I like here is that demand for AstraZeneca’s products, which includes treatments for cardiovascular diseases and various types of cancer, is generally stable across the economic cycle.

However, the pharmaceutical giant is doing much better than stable. In 2023, its revenue rose 6% year on year to $45,8bn, despite a huge decline from its Covid medicines (it has now withdrawn its Covid vaccine due to low demand).

Excluding these, total revenue actually jumped 15% and product sales increased 14%. And core earnings per share (EPS) advanced 15% to $7.26.

CEO Pascal Soriot said: “We expect another year of strong growth in 2024, driven by continued adoption of our medicines across geographies. Our differentiated and growing portfolio of approved medicines, global reach and rich R&D pipeline give us confidence that we will continue to deliver industry-leading growth.”

Looking ahead, the oncology market is sadly set to grow due to rising cases of cancer globally. But AstraZeneca is a world-leader here. Its blockbuster cancer drug, Tagrisso, has proven to reduce the risk of the disease spreading by an incredible 84% in patients with a type of Stage 3 lung cancer.

Risks to consider

After rising 16% year to date, the stock isn’t exactly cheap at 19.2 times forward earnings. That’s far less than Footsie peer GSK, which is trading at just 10.1 times forecast earnings for 2024.

However, I think this disparity simply reflects the much faster growth of AstraZeneca, its far deeper pipeline of drugs, and GSK’s ongoing litigation issues. A judge in the US has just allowed over 70,000 lawsuits alleging GSK’s discontinued heartburn drug, Zantac, caused cancer.

Of course, that doesn’t mean AstraZeneca couldn’t one day face similar problems. Litigation is a key risk in the pharma industry, as is adverse regulation, patent expirations, and clinical trial failures.

I’d still invest today

Longer term though, I’m very bullish on the sector and AstraZeneca in particular.

This is due to the powerful trend of a rapidly ageing global population, especially in China where the company has a growing presence. This could boost demand for its medicines for decades.

And with the firm aiming to grow revenue by 75% to $80bn by 2030, I think the shares will continue to handily outperform the FTSE 100. That’s why I treated myself to a few not long back.

Should you buy HSBC now?

Don’t make any big decisions yet.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.

And he believes they could bring spectacular returns over the next decade.

Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows...

When such enormous changes hit a big industry, informed investors can potentially get rich.

So, with his new report, Mark’s aiming to put more investors in this enviable position.

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

Is the rare dip in this FTSE powerhouse’s share price just the right time for investors to consider buying it?

This FTSE 100 banking giant has seen its price tumble following the US tariffs news, but could the rare dip…

Read more »

Investing Articles

After an 18% fall, is Rolls-Royce’s share price now just too cheap for me to ignore?

Rolls-Royce’s share price was caught in the recent FTSE 100 sell-off. But now might be the time for me to…

Read more »

Investing Articles

11% yield! Could this UK stock  be a huge opportunity for investors targeting a second income?

An double-digit dividend yield could be second-income buying opportunity if the stock market is underestimating this UK translation company. 

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

This FTSE 250 REIT’s been unaffected by Trump’s tariffs. And it’s yielding 8.3%

Our writer’s found a FTSE 250 real estate investment trust that hasn’t been caught in the fallout from ‘Liberation Day’.…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Dividend Shares

Blimey, what’s happened to the Barclays share price?

After hitting a 15-year high at the end of February, the Barclays share price has plunged in the past two…

Read more »

Dividend Shares

On 8.6 times earnings and a cash yield of 9%, this FTSE 250 share seems too cheap

It's been a rough week or so for UK shareholders, with the FTSE 100 and FTSE 250 both plunging. Yet…

Read more »

Smiling senior white man talking through telephone while using laptop at desk.
Investing Articles

Here’s why I just bought this gold stocks fund for my SIPP!

I think investing in gold stocks could be the best way to capitalise on bullion's bull run. Here's a top…

Read more »

Investing Articles

How much passive income an investor could earn if they put £250 a month in an ISA at 40

Harvey Jones shows how small, regular investments can flourish into a generous passive income to secure a comfortable retirement years…

Read more »